VivoSeq
Gastroenterology

Pouchitis

19

Pipeline Programs↗

5

Active Trials↗

13

Companies Involved↗

Pouchitis is an emerging landscape with 19 programs across 13 companies. The most active players are Jiangsu Topcel-KH Pharmaceutical Co., Ltd., Ocera Therapeutics, Pfizer. 6 therapies are approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

47/100

Pipeline Velocity

15/100

Mech. Concentration

9/100

Completion Rate

60/100

Attrition Rate

25/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

J

Jiangsu Topcel-KH Pharmaceutical Co., Ltd.

1 program

Phase 1O

Ocera Therapeutics

1 program

Phase 2Pfizer logo

Pfizer

1 program

Phase 2P

Prism Pharmaceuticals

1 program

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 2Takeda logo

Takeda

2 programs

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

67%

Small molecule

14 of 21 classified programs — the dominant modality here.

33%ALL OTHERSMonoclonal antibody419%Peptide15%RNA therapy15%Cell therapy15%

Small molecule leads; the ring shows all 21 classified programs, each share of the total. Modality classified for 96% of 25 pipeline programs.

Analysis

Trial Status

20

clinical trials

Completed9 · 45%
Terminated4 · 20%
Recruiting3 · 15%
Not yet recruiting2 · 10%
Withdrawn1 · 5%
Suspended1 · 5%

Clinical Trials

Trial Activity

20 trials

Fecal Microbiota Transplant for Patients With Chronic Pouchitis
Recruiting·—·Phase 1·NCT05829109·16 enrolled
Rifaximin for the Secondary Prevention of Recurrent Pouchitis
Recruiting·UUniversity of North Carolina, Chapel Hill·Phase 4·NCT06312683·16 enrolled
A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis
Recruiting·Takeda logoTakeda·Phase 3·NCT06443502·30 enrolled
GUselkumAb inteRvention and DIet evaluAtioN for Pouchitis
Not yet recruiting·UUniversitaire Ziekenhuizen KU Leuven·Phase 4·NCT06916390·20 enrolled
Etrasimod as Prevention of Pouchitis
Not yet recruiting·—·Phase 2·NCT07486921·40 enrolled
Study of the Safety and Efficacy of AMT-101 in Subjects With Pouchitis
Completed·—·Phase 2·NCT04741087·22 enrolled
A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis
Completed·Takeda logoTakeda·Phase 4·NCT02790138·102 enrolled
Efficacy of Alicaforsen in Pouchitis Patients Who Have Failed to Respond to at Least One Course of Antibiotics
Completed·AAtlantic Pharmaceuticals Ltd·Phase 3·NCT02525523·138 enrolled
Stelara fOr ChRonic AntibioTic rEfractory pouchitiS
Completed·UUniversitaire Ziekenhuizen KU Leuven·Phase 3·NCT04089345·20 enrolled
Safety and Efficacy of AST-120 in the Treatment of Pouchitis
Completed·OOcera Therapeutics·Phase 2·NCT00583076·19 enrolled
Adalimumab in the Treatment of Chronic Pouchitis
Completed·OOdense University Hospital·Phase 3·NCT01670240·13 enrolled
Study of Sc-FOS for Pouchitis Prevention
Completed·MMayo Clinic·Phase 1·NCT02203955·13 enrolled
Fecal Microbiota Transplantation (FMT) in the Treatment of Pouchitis
Completed·HHelsinki University Central Hospital·Phase 2·NCT03378921·26 enrolled
Fecal Microbiota Transplant (FMT) for Pouchitis
Completed·—·Phase 1·NCT02428361·19 enrolled
A Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of CLF065 in the Treatment of Chronic Pouchitis
Suspended·TThe Scripps Research Institute·Phase 2·NCT07226050·20 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)